The molecular aspect of anti-glaucomatous eye drops - are we harming our patients?

Keyphrases

• Eye Drops 100%
• Glaucomatous 100%
• Molecular Aspects 100%
• Intraocular Pressure 50%
• Preservatives 50%
• PH Value 50%
• Molecular Components 50%
• Benzalkonium Chloride 50%
• Active Pharmaceutical Ingredients 50%
• Prostaglandin Analogs 25%
• Disease Control 25%
• Phosphate 25%
• Deep Tissue 25%
• Topical Treatment 25%
• Harmful Effects 25%
• Viscosity 25%
• Glaucoma 25%
• Carbonic Anhydrase Inhibitors 25%
• Glaucoma Patients 25%
• Ocular Surface 25%
• Adrenergic Agonist 25%
• Molecular Properties 25%
• Irreversible Blindness 25%
• Glaucoma Treatment 25%
• Rho Kinase Inhibitor 25%
• Ocular Discomfort 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Glaucoma 100%
• Side Effect 66%
• Benzalkonium Chloride 66%
• Disease 33%
• Buffer 33%
• Rho Kinase Inhibitor 33%
• Adrenergic Receptor Blocking Agent 33%
• Adrenergic Receptor Stimulating Agent 33%
• Carbonate Dehydratase Inhibitor 33%
• Prostaglandin Analogue 33%
• Eye Discomfort 33%